Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK364735 and · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| GSK364735 oral solution and oral tablets | DRUG | - |
Inclusion criteria: * The subject is healthy with no clinically significant problems identified by the physician. * Females of non-childbearing potential and males surgically sterile or agrees to birth control. * Body mass Index (BMI) of 19-29.9 (kg/m2). Exclusion criteria: * As a result of the p...
Top 20 of 28 competitors
GSK364735 is an investigational small molecule being developed for the treatment of HIV infection, including HIV-1 infection. It is being studied in adults with HIV who have not previously been treated with integrase inhibitors. The drug is currently in clinical development and is not approved by the FDA.
GSK364735 is being studied as a monotherapy in integrase-naive HIV-1 infected adults, indicating it targets the HIV integrase enzyme. By inhibiting integrase, the drug aims to block viral DNA integration into host cells, thereby reducing viral replication. This mechanism is being evaluated in clinical trials.
GSK364735 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating HIV infection.
GSK364735 is in Phase 2 clinical development. It has completed a Phase 1 study in healthy subjects and a Phase 2 study in HIV-1 infected adults. The drug is investigational and has not received FDA approval. Its development status is based on completed trials.
GSK364735 has been studied in two completed clinical trials. NCT00386347 was a Phase 1 study evaluating formulations and food effects in healthy subjects. NCT00398125 was a Phase 2 monotherapy versus placebo study over 10 days in integrase-naive HIV-1 infected adults. Both trials were conducted in the United States.
GSK364735 is not known to have alternative names. It is identified by its compound number in clinical trials and is being developed solely by GSK plc. No other names or aliases have been associated with this drug in the available clinical trial information.